Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dogwood Therapeutics, Inc.VIRI · Entity 6845 | Director | February 26, 2024 | February 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dogwood Therapeutics, Inc.
Report date February 26, 2024 · Filed February 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2034-02-26 | Direct | 2,917 |
Reported balance
After 2024-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-26 · Grant · Acquired 2,917 · Balance 2,917 F1: The stock option will vest 100% on February 26, 2025, one year following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest 100% on February 26, 2025, one year following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2024 Filed Feb 28, 2024 18:14 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 2,917 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-24-005686 · form4-02282024_060247.xml · derivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,917 Underlying: Common Stock · 2,917 shares Expires 2034-02-26 F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date. Read SEC document |
| August 21, 2023 Filed Aug 22, 2023 19:57 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 15,335 | $1.30 | $19,992.24 |
DisclosureSEC source: 0001415889-23-012474 · form4-08222023_070830.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · 401 (k) Account Disclosed balance after: 52,045 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.26 to $1.36, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 17:53 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001415889-23-009983 · form4-06202023_050635.xml · derivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option will vest 100% on June 14, 2024, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:08 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007094 · form4-06302022_110603.xml · derivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| May 18, 2022 Filed May 19, 2022 15:44 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 241 | $4.50 | $1,084.50 |
DisclosureSEC source: 0001415889-22-005272 · form4-05192022_080545.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 36,710 F1 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| May 17, 2022 Filed May 18, 2022 15:24 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 13,450 | $4.38 | $58,913.69 |
DisclosureSEC source: 0001415889-22-005214 · form4-05182022_080517.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 36,469 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.94 to $4.57, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 15:55 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 600 | $4.94 | $2,964.48 |
DisclosureSEC source: 0001415889-22-003465 · form4-03302022_080315.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 23,019 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.94 to $4.97, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 18:52 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 2,197 | $5.46 | $12,001.55 |
DisclosureSEC source: 0001415889-22-003314 · form4-03242022_110324.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 22,419 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.37 to $5.48, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Reflects corrected holdings, as prior reports incorrectly understated indirect holdings and overstated direct holdings, by 1,500 shares. F3 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 20:30 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 4,180 | $5.98 | $24,997.65 |
DisclosureSEC source: 0001415889-22-000846 · form4-01282022_120112.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 18,722 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.80 to $6.27, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 20:23 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 2,215 | $5.43 | $12,033.87 |
DisclosureSEC source: 0001415889-22-000167 · form4-01042022_120157.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 14,542 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.20 to $5.70, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 18:28 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 8,827 | $5.66 | $49,997.01 |
DisclosureSEC source: 0001415889-21-006174 · form4-12222021_101232.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 12,327 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.375 to $5.8799, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 17:36 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 942 | $6.32 | $5,950.61 |
DisclosureSEC source: 0001415889-21-003569 · form4-07092021_100738.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,734 F1 · shares: This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · balance_after: Does not include 18,201 shares that were previously reported on the reporting person's Form 3 and prior Forms 4. Such shares were included in the person's holdings in error. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 19:26 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003158 · form4-06232021_120654.xml · derivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 00:54 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 3,500 | $7.47 | $26,145.00 |
DisclosureSEC source: 0001104659-21-010386 · tm214953-2_4seq1.xml · nonDerivative · entry 2 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Account Disclosed balance after: 3,500 F1 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 801 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-21-010386 · tm214953-2_4seq1.xml · derivative · entry 3 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 801 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: The Reporting Person provided notice of exercise to the Issuer on January 20, 2021 and the Company authorized the issuance of the shares pursuant to such exercise on January 28, 2020. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | Exercise / conversionCommon Stock | 801 | $7.80 | $6,247.80 |
DisclosureSEC source: 0001104659-21-010386 · tm214953-2_4seq1.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 22, 2020 01:10 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 1,500 | $11.98 | $17,970.00 |
DisclosureSEC source: 0001104659-20-138199 · tm2039099-1_4.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,192 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.